995 Intraprostatic Injection of Botulinum Toxin Type a Causes a Long-Lasting Improvement in Luts and Urinary Flow in Patients With Benign Prostatic Enlargement Refractory to Standard Medical Therapy

The use of botulinum toxin in benign prostatic hyperplasia

“…All the studies in our review reported a fall in the IPSS score from the baseline levels, except Kuo,40 Silva et al,21, 22 Park et al,12 and Sreedar et al25 A statistically significant reduction was reported in 13 studies14, 16–20, 23, 24, 26, 36, 37, 41, 42 (54.1%) with a mean reduction of 10.8 ± 2.66 points. Maria18 reported that the reduction in the IPSS score was maintained after 12 months' follow‐up (8.9 + 3.2) P = 0.001 and McVary et al36 observed a fall of 37.4% in the IPSS scores after 12 months.…”

“…The Quality of Life score fell significantly in eight series (41.6%) in all publications, with a mean decrease of 2.1 + 0.62 points 14, 16, 18, 20, 23, 26, 37, 42…”

“…IPSS ≥ 8 20 LUTS due to BPH with prostate volume (PV) < 30 cm 3 ,16 PV > 40 cm 3 ,23 PV between 30 and 50 cm 3 ,24 PV > 60 cm 3 (20). Associated comorbidity 21, 22, 25, 26 Inadequate response to medical treatment (5 ARIS or α‐blockers) or intolerance to this treatment 11, 12, 16, 22…”

“…The remaining studies were comprised of ten prospective cohorts,11, 16, 19, 20–23, 25, 37, 38 together with communications to congresses (presented subsequently in the supplements to their respective journals) 17, 24, 26, 34, 39, 40–42…”

“…Other authors, such as Chuang et al,11, 16, 23, 27 Park et al,12 Maria et al,18 Brisinda et al,19 Silva et al,21, 22, 41 Kuo and Liu,14 Kuo,37, 40 Jasinski et al,34 Karsenty et al,35 Agrawal et al,38 and Guercini et al39 used Onabotulinumtoxin A (Botox, Cosmetic, Allergan, Inc., Irvine, CA). However, many other authors do not communicate the subtype used in their works 13, 15, 17, 24–26, 36, 38…”